Finance

Lists
CLBT:NASDAQ
Cellebrite DI Ltd
$11.31
+1.34%
(+0.15) 1D
Nov 19, 3:37:49 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLBT...
Open
$11.22
High
$11.50
Low
$11.22
Mkt. cap
2.84B
Avg. vol.
2.07M
Volume
1.03M
P/E ratio
44.19
52-wk high
$19.39
52-wk low
$9.58
EPS
$0.26
Beta
1.06
Shares outstanding
251.34M
No. of employees
1K
Open
$11.22
High
$11.50
Low
$11.22
Mkt. cap
2.84B
Avg. vol.
2.07M
Volume
1.03M
P/E ratio
44.19
52-wk high
$19.39
52-wk low
$9.58
EPS
$0.26
Beta
1.06
Shares outstanding
251.34M
No. of employees
1K
News stories
From web sources and news partners
Profile
Cellebrite DI Ltd. is an Israeli digital forensics company headquartered in Petah Tikva that provides tools for law enforcement agencies as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Their flagship product series is the Cellebrite UFED. Cellebrite's largest shareholder is Sun Corporation, which is based in Nagoya, Japan. Cellebrite has fourteen offices around the world including business centers in Washington, D.C., Munich, and in Singapore. In 2021, the Cellebrite company was valued at approximately $2.4 billion. Wikipedia
About Cellebrite DI Ltd
CEO-
Employees1.28K
Founded1999
Headquarters-
SectorInformation Technology
IndustryApplication software
Analyst ratings
Based on 3 analysts giving stock ratings to CLBT in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for CLBT in the last 3 months.
Highest
Current $11.31
$15.00 (+32.63%)
Average
$15.00 (+32.63%)
Lowest
$15.00 (+32.63%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Essex
J.P. Morgan
Buy
Maintained
$15.00
+32.6%
11/13/2026
Rudy Kessinger
D.A. Davidson
Buy
Maintained
$15.00
+32.6%
09/15/2026
Jeff Van Rhee
Craig-Hallum
Buy
Maintained
-
-
09/02/2026
Frank Takkinen
Lake Street
Buy
Reiterated
$15.00
+32.6%
08/14/2026
Unknown Analyst
Deutsche Bank
Buy
Maintained
$14.00
+23.8%
08/14/2026
Unknown Analyst
J.P. Morgan
Buy
Reiterated
$16.00
+41.5%
08/14/2026
Mike Cikos
Needham
Buy
Maintained
$12.50
+10.5%
08/14/2026
Shaul Eyal
TD Cowen
Buy
Maintained
$15.00
+32.6%
08/13/2026
Jonathan Ho
William Blair
Buy
Maintained
-
-
08/13/2026
Eric Martinuzzi
Lake Street
Buy
Reiterated
$21.00
+85.7%
05/14/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
$0.17 / $0.16
+7.54%beat
Revenue / Est. (USD)
149.02M / 145.89M
+2.15%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
128.82M
128.30M
131.14M
149.02M
Cost of goods sold
19.69M
22.42M
25.21M
27.98M
Cost of revenue
19.69M
22.42M
25.21M
27.98M
Research and development expenses
29.86M
35.87M
35.96M
36.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
58.46M
60.89M
63.02M
57.78M
Operating expense
88.32M
96.76M
98.98M
94.17M
Total operating expenses
108.02M
119.18M
124.19M
122.15M
Operating income
20.80M
9.12M
6.95M
26.88M
Other non operating income
-482.00K
-
-195.00K
-
EBT including unusual items
26.27M
13.63M
11.19M
31.74M
EBT excluding unusual items
26.27M
13.63M
11.19M
31.74M
Income tax expense
5.01M
2.70M
4.82M
5.08M
Effective tax rate
19.07%
19.77%
43.05%
16.02%
Other operating expenses
-
-
-
-
Net income
21.26M
10.94M
6.37M
26.66M
Net profit margin
16.50%
8.53%
4.86%
17.89%
Earnings per share
0.14
0.12
0.11
0.17
Interest and investment income
5.21M
4.52M
5.54M
4.87M
Interest expense
-
-
-
-
Net interest expenses
5.21M
4.52M
5.54M
4.87M
Depreciation and amortization charges
-
-
-
-
EBITDA
24.75M
16.12M
15.86M
36.21M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps